Targeting specific disease metrics, such as reducing apob with a pcsk9 inhibitor, can measurably reduce disease risk.

“when you give somebody a pcsk9 inhibitor which specifically targets a protein that allows the body to clear more apob particles out of circulation it is by no means targeting one of those nine pillars but it's having a measurable impact on reducing their risk of disease”